| Literature DB >> 28376900 |
Ziwei Feng1, Cheng Tao2, Jian Zhu2, Jinhu Chen2, Gang Yu1, Shaohua Qin1, Yong Yin2, Dengwang Li3.
Abstract
BACKGROUND: For cervical carcinoma cases, this study aimed to evaluate the quality of intensity-modulated radiation therapy (IMRT) plans optimized by biological constraints. Furthermore, a new integrated strategy in biological planning module was proposed and verified.Entities:
Keywords: Biology optimization; Cervical carcinoma; Intensity-modulated radiation therapy; Normal tissue complication probability; Physical optimization; Tumor control probability
Mesh:
Year: 2017 PMID: 28376900 PMCID: PMC5379684 DOI: 10.1186/s13014-017-0784-1
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Clinical requirements to target and OARs
| Structures | Constraints | ||
|---|---|---|---|
| Mean dose | Dose volume | ||
| PTV | - | At least 95% volume of PTV to receive the prescribed dose | |
| OAR | Rectum | <35 Gy | Less than 40% volume to exceed 40 Gy |
| Bladder | <35 Gy | Less than 40% volume to exceed 40 Gy | |
| Femur-heads | <25 Gy | Less than 5% volume to exceed 40 Gy | |
The physical constraints used in DVO
| Structures | Constraints | Parameters | |
|---|---|---|---|
| PTV | Min dose | 54 Gy | |
| Dose/volume | V97 > 54.5 Gy | ||
| Dose/volume | V3 < 57.5 Gy | ||
| Max dose | 58 Gy | ||
| OAR | Rectum | Dose/volume | V40 < 35 Gy, and two extra dose/volume constraints for reducing the mean dose |
| Bladder | Dose/volume | V40 < 35 Gy, and two extra dose/volume constraints for reducing the mean dose | |
| Femur-heads | Dose/volume | V5 < 35Gy, and two extra dose/volume constraints for reducing the mean dose | |
| B-Pa | Max dose | 50 Gy | |
aThe assistance organ Body-PTV (B-P) was defined as the body volume in the CT data set minus the PTV leaving a 0.3 cm gap
The biological constraints and additional physical constrains used in BMO
| Structures | Model or constraints | Parameters | |
|---|---|---|---|
| PTV | TCP Poisson-LQ |
| |
| Target EUD | D = 54Gy, a = 0.1 | ||
| Max Dose | D = 58Gy | ||
| Uniformity constraint | Std. dev = 2% | ||
| OARs | Rectum | NTCP LKBar |
|
| NTCP LKBbr |
| ||
| NTCP Poisson-LQcr |
| ||
| Max EUD | D (variable), a = 1 | ||
| Bladder | NTCP LKBab |
| |
| NTCP Poisson-LQbb |
| ||
| Max EUD | D (variable), a = 1 | ||
| Femur-heads | NTCP Poisson-LQ |
| |
| Max EUD | D (variable), a = 1 | ||
| Small bowela | NTCP Poisson-LQ |
| |
| B-P | Max Dose | D = 50Gy | |
The superscripts of NTCP models denote the different biological models of rectum and bladder which will be used in the results section
aThe small bowel was not involved in biological optimization. The biological parameter was just used for the biological evaluation
Evaluation of DVO plans, BMO plans and ISO plans
| Structures | Parameters | DVO | BMO | ISO | P1 | P2 | P3 | |
|---|---|---|---|---|---|---|---|---|
| PTV | D98 (Gy) | 54.57 ± 0.46 | 53.42 ± 0.36 | 54.18 ± 0.38 | <0.01 | <0.01 | <0.01 | |
| D2 (Gy) | 58.82 ± 0.22 | 58.72 ± 0.28 | 58.89 ± 0.26 | 0.27 | 0.12 | 0.18 | ||
| V95 (%) | 99.13 ± 0.82 | 96.79 ± 0.81 | 98.31 ± 0.91 | <0.01 | <0.01 | <0.01 | ||
| HI | 0.08 ± 0.01 | 0.10 ± 0.01 | 0.09 ± 0.01 | <0.01 | <0.01 | <0.01 | ||
| CI | 0.82 ± 0.04 | 0.71 ± 0.05 | 0.76 ± 0.04 | <0.01 | <0.01 | <0.01 | ||
| TCP | 15.39 ± 0.06 | 15.55 ± 0.58 | 15.39 ± 0.05 | 0.22 | 0.23 | 0.97 | ||
| OAR | Rectum | V20 (%) | 97.55 ± 3.41 | 95.21 ± 6.98 | 92.66 ± 6.36 | 0.10 | <0.01 | <0.01 |
| V30 (%) | 63.43 ± 10.06 | 69.67 ± 12.80 | 60.29 ± 12.76 | 0.01 | <0.01 | 0.17 | ||
| V40 (%) | 26.46 ± 10.90 | 24.35 ± 12.44 | 24.24 ± 10.14 | 0.13 | 0.93 | 0.07 | ||
| V50 (%) | 6.16 ± 5.63 | 4.35 ± 5.82 | 7.62 ± 10.66 | <0.01 | 0.02 | 0.31 | ||
| Dmax (Gy) | 56.55 ± 2.06 | 54.29 ± 2.93 | 56.00 ± 2.01 | <0.01 | <0.01 | 0.13 | ||
| Dmean (Gy) | 34.62 ± 2.81 | 34.49 ± 2.68 | 33.49 ± 2.59 | 0.66 | <0.01 | <0.01 | ||
| NTCP | 0.19 ± 0.17ar | 0.11 ± 0.12ar | 0.14 ± 0.13ar | <0.01 | <0.01 | <0.01 | ||
| Bladder | V20 (%) | 95.35 ± 4.50 | 93.90 ± 7.13 | 91.29 ± 7.79 | 0.35 | <0.01 | 0.03 | |
| V30 (%) | 62.10 ± 8.71 | 63.32 ± 8.90 | 58.06 ± 8.12 | 0.47 | <0.01 | <0.01 | ||
| V40 (%) | 29.08 ± 7.07 | 30.27 ± 7.29 | 29.68 ± 6.71 | 0.25 | 0.28 | 0.54 | ||
| V50 (%) | 9.79 ± 5.96 | 8.86 ± 6.44 | 9.83 ± 6.80 | 0.07 | 0.02 | 0.93 | ||
| Dmax (Gy) | 58.95 ± 1.38 | 58.22 ± 1.75 | 58.63 ± 1.72 | <0.01 | 0.09 | 0.09 | ||
| Dmean (Gy) | 34.29 ± 2.19 | 34.65 ± 2.22 | 33.92 ± 2.13 | 0.15 | <0.01 | 0.12 | ||
| NTCP | 0.18 ± 0.20ab | 0.14 ± 0.19 ab | 0.16 ± 0.20ab | 0.03 | 0.15 | <0.01 | ||
| Small bowel | V20 (%) | 52.02 ± 8.45 | 51.37 ± 9.77 | 51.77 ± 8.90 | 0.44 | 0.35 | 0.41 | |
| V45 (%) | 0.87 ± 1.48 | 0.83 ± 1.62 | 0.84 ± 1.79 | 0.32 | 0.26 | 0.30 | ||
| NTCP | 0.94 ± 1.53 | 0.89 ± 1.74 | 0.90 ± 1.88 | 0.39 | 0.23 | 0.28 | ||
| B-P | Dmax (Gy) | 57.59 ± 3.05 | 58.39 ± 1.88 | 58.04 ± 2.41 | 0.17 | 0.27 | 0.36 | |
The p value p1, p2, p3 were represented of the p value between DVO and BMO, BMO and ISO, DVO and ISO, respectively. The superscripts of NTCP values denote the biological models of rectum and bladder which listed in Table 3 used for IMRT optimization. ar: LKB with =80Gy, =3.9, N = 0.06, M = 0.15 for rectum; ab: LKB with =62Gy, =6, N = 0.13, M = 0.11 for bladder
Evaluation of BMO plans with different biological models
| Biological comparison | Structures | NTCP value | NTCP value | Paired t-test p |
|---|---|---|---|---|
| Rectum: ar VS. br | Rectum | 0.11 ± 0.12ar | 0.33 ± 0.19br | <0.01 |
| Bladder | 0.14 ± 0.19ab | 0.14 ± 0.19ab | - | |
| Rectum: ar VS. cr | Rectum | 0.11 ± 0.12ar | 0.01 ± 0.02cr | <0.01 |
| Bladder | 0.14 ± 0.19ab | 0.14 ± 0.19ab | - | |
| Bladder: ab VS. bb | Rectum | 0.11 ± 0.12ar | 0.11 ± 0.12ar | - |
| Bladder | 0.14 ± 0.19ab | 0.00 ± 0.00bb | <0.01 |
The superscripts of NTCP values denote the different biological models of rectum and bladder which listed in Table 3 used for IMRT optimization. ar: LKB with =80Gy, =3.9, N = 0.06, M = 0.15 for rectum; br: LKB with =81.8Gy, =3, N = 0.29, M = 0.22 for rectum; cr: Poisson-LQ with =80Gy, =2.2, =3Gy, s = 1 for rectum; ab: LKB with =62Gy, =6, N = 0.13, M = 0.11 for bladder; bb: Poisson-LQ with =80Gy, =3, =3Gy, s = 0.18 for bladder
Fig. 1The mean DVH averaged over 20 patients of DVO, BMO and ISO plans
Fig. 2Dose distribution of one specific patient. a dose distribution of DVO plan; b dose distribution of BMO plan; c dose distribution of ISO plan